Intravenous versus oral iron for iron deficiency anaemia in pregnant Nigerian women (IVON): a randomised controlled trial.
Women Randomized
FCM Group (Ferrous Carboxymaltose)
FS Group (Ferrous Sulphate)
as at Thursday, 15th December, 2022.
Anaemia in pregnancy (AIP) remains a critical global health problem especially in low- and middle-income countries (LMICs), affecting 46% of pregnant women in Africa and 49% in Asia. Iron deficiency anaemia (IDA) is the commonest cause of AIP, accounting for 50-75% of AIP.
Our aim is to compare the effectiveness of intravenous ferric carboxymaltose (intervention) versus oral ferrous sulphate (control) for treating anaemia and IDA in pregnancy and to measure the acceptability, feasibility, fidelity (implementation outcomes) and the cost-effectiveness of intravenous iron among pregnant Nigerian women with moderate and severe anaemia, and IDA at 20–32 weeks’ gestation.
Iron deficiency anaemia (IDA) is the commonest cause of AIP, accounting for 50-75% of AIP. We aim to compare the effectiveness of intravenous ferric carboxymaltose (intervention) versus oral ferrous sulphate (control) for treating anaemia and IDA in pregnancy and to measure acceptability, feasibility, fidelity (implementation outcomes) and the cost-effectiveness of intravenous iron among pregnant Nigerian women with moderate and severe anaemia at 20–32 weeks’ gestation.
Prof. Bosede B. Afolabi MBChB (OAU), DM(Notts), FRCOG (UK), FWACS, FMCOG
Department of Obstetrics & Gynaecology
College of Medicine, University of Lagos/Idi-Araba, Lagos.
Please note: This publication is based on research funded in part by the Bill & Melinda Gates Foundation. The findings and conclusions contained within are those of the authors and do not necessarily reflect positions or policies of the Bill & Melinda Gates Foundation.
